Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurokawa, Y.
Right arrow Articles by Monden, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurokawa, Y.
Right arrow Articles by Monden, M.
Clinical Cancer Research Vol. 10, 6029-6038, September 15, 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Molecular Prediction of Response to 5-Fluorouracil and Interferon-{alpha} Combination Chemotherapy in Advanced Hepatocellular Carcinoma

Yukinori Kurokawa1,2, Ryo Matoba2, Hiroaki Nagano1, Masato Sakon1, Ichiro Takemasa1, Shoji Nakamori1, Keizo Dono1, Koji Umeshita1, Noriko Ueno2, Shin Ishii3, Kikuya Kato2 and Morito Monden1

1 Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan; and 2 Taisho Laboratory of Functional Genomics and 3 Laboratory of Theoretical Life Science, Nara Institute of Science and Technology, Nara, Japan

ABSTRACT

Purpose: The prognosis of hepatocellular carcinoma (HCC) is very poor, particularly in patients with tumors that have invaded the major branches of the portal vein. Combination chemotherapy with intra-arterial 5-fluorouracil and subcutaneous interferon-{alpha} has shown promising results for such advanced HCC, but it is important to develop the ability to accurately predict chemotherapeutic responses.

Experimental Design: We analyzed the expression of 3,080 genes using a polymerase chain reaction-based array in 20 HCC patients who were treated with combination chemotherapy after reduction surgery. After unsupervised analyses, a supervised classification method for predicting chemotherapeutic responses was constructed. To minimize the number of predictive genes, we used a random permutation test to select only significant (P < 0.01) genes. A leave-one-out cross-validation confirmed the gene selection. We also prepared an additional 11 cases for validation of predictive performance.

Results: Hierarchical clustering analysis and principal component analysis with all 3,080 genes revealed distinct gene expression patterns in responders (those with complete response or partial response) and nonresponders (those with stable disease or progressive disease) to the combination chemotherapy. Using a weighted-voting classification method with either all genes or only significant genes as assessed by permutation testing, the objective responses to treatment were correctly predicted in 17 of 20 cases (accuracy, 85%; positive predictive value, 100%; negative predictive value, 80%). Moreover, patients in the validation dataset could be classified into two distinct prognostic groups using 63 predictive genes.

Conclusions: Molecular analysis of 63 genes can predict the response of patients with advanced HCC and major portal vein tumor thrombi to combination chemotherapy with 5-fluorouracil and interferon-{alpha}.




This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
R. W. C. Pang, J. W. Joh, P. J. Johnson, M. Monden, T. M. Pawlik, and R. T. P. Poon
Biology of Hepatocellular Carcinoma
Ann. Surg. Oncol., April 1, 2008; 15(4): 962 - 971.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Shirahata, K. Iwao-Koizumi, S. Saito, N. Ueno, M. Oda, N. Hashimoto, J. A. Takahashi, and K. Kato
Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis
Clin. Cancer Res., December 15, 2007; 13(24): 7341 - 7356.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. K. Abou-Alfa, L. Schwartz, S. Ricci, D. Amadori, A. Santoro, A. Figer, J. De Greve, J.-Y. Douillard, C. Lathia, B. Schwartz, et al.
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
J. Clin. Oncol., September 10, 2006; 24(26): 4293 - 4300.
[Abstract] [Full Text] [PDF]


Home page
Microbiol. Mol. Biol. Rev.Home page
G. N. Vemuri and A. A. Aristidou
Metabolic Engineering in the -omics Era: Elucidating and Modulating Regulatory Networks
Microbiol. Mol. Biol. Rev., June 1, 2005; 69(2): 197 - 216.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.